ArticleHealth economics review2024

The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China.

Shuyan Gu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.